Please use this identifier to cite or link to this item:
https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7273
Title: | Small-cell lung cancer - an update on targeted and immunotherapies |
Authors: | McNamee, Nicholas;da Silva, Ines Pires;Nagrial, Adnan M.;Gao, Bo |
WSLHD Author: | McNamee, Nicholas;da Silva, Ines Pires;Nagrial, Adnan M.;Gao, Bo |
Issue Date: | 2023 |
Citation: | International journal of molecular sciences 24(9):8129, 2023 |
Abstract: | Small-cell lung cancer (SCLC) is an aggressive disease with distinct biological and clinical features. The clinical course of SCLC is generally characterised by initial sensitivity to DNA-damaging therapies, followed by early relapse and broad cross resistance to second line agents. Whilst there has been an enormous expansion of effective targeted and immune-based therapeutic options for non-small cell lung cancer (NSCLC) in the last decade, little improvement has been achieved in SCLC treatment and survival due, at least in part, to underappreciated inter- and intra-tumoral heterogeneity. Here we review the current treatment paradigm of SCLC including recent advances made in utilizing immunotherapy and the challenges of identifying a predictive biomarker for immunotherapy response. We examine emerging new targeted therapies, combination immunotherapy and future directions of SCLC treatment research. |
URI: | https://wslhd.intersearch.com.au/wslhdjspui/handle/1/7273 |
DOI: | https://dx.doi.org/10.3390/ijms24098129 |
Journal: | International journal of molecular sciences |
Type: | Journal Article |
Study or Trial: | Review |
Department: | Oncology |
Facility: | Blacktown Westmead |
Affiliated Organisations: | Blacktown and Westmead Hospitals, Sydney, NSW, Australia Westmead Clinical School, University of Sydney, Sydney, NSW, Australia |
Keywords: | Lung Neoplasms Carcinoma, Non-Small-Cell Lung Immunotherapy |
Appears in Collections: | Blacktown Mount Druitt Hospital |
Files in This Item:
There are no files associated with this item.
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.